EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3

Kristian Reich iD, Eric Simpson, Andreas Wollenberg iD, Robert Bissonnette, Masatoshi Abe, Tracy Cardillo, Jonathan Janes, Luna Sun, Sherry Chen, Jonathan I Silverberg iD

British Journal of Dermatology · 10.02.2023 · 188 (2) · 208-217

DOI: 10.1093/bjd/ljac057 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift British Journal of Dermatology, online erschienen am 17.11.2022. Verfasst von Kristian Reich und 9 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Center-Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Baricitinib, an oral, selective Janus kinase 1/2 inhibitor, demonstrated long-term efficacy in moderate-to-severe atopic dermatitis in an ongoing double-blind, phase III, long-term extension study, BREEZE-AD3 (NCT03334435).

Objectives

To evaluate the efficacy and safety of downtitration and treatment withdrawal in a substudy of BREEZE-AD3.

Methods

The substudy included patients (N = 526) treated with baricitinib 4 mg or 2 mg at entry into BREEZE-AD3 who achieved a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD®) scale score of 0 (clear), 1 (almost clear) or 2 (mild) at week 52. Patients treated with baricitinib 4 mg were rerandomized to baricitinib 4 mg (continuous dosing), baricitinib 2 mg (downtitration) or placebo (treatment withdrawal, 4-mg cohort), and patients treated with baricitinib 2 mg were rerandomized to baricitinib 2 mg (continuous dosing), baricitinib 1 mg (downtitration), or placebo (treatment withdrawal, 2-mg cohort). After 16 weeks, we assessed the proportion of patients with vIGA-AD® 0/1, vIGA-AD® 0/1/2, vIGA-AD® ≥ 3 (loss of response; criterion to readminister the original baricitinib dose) and for patients who were readministered the original baricitinib dose, we assessed the proportion of patients who recaptured vIGA-AD® 0/1/2 within 16 weeks of treatment readministration (patients in the continuous dosing maintained the same dose).

Results

For the continuous dosing, downtitration, and treatment withdrawal groups 51%, 45% and 30% of patients in the 4-mg cohort achieved vIGA-AD® 0/1 and 87%, 61% and 50% of patients achieved vIGA-AD® 0/1/2, respectively. For the 2-mg cohort, the respective proportions of patients were 48%, 42% and 25% for vIGA-AD® 0/1 and 92%, 71% and 45% for vIGA-AD® 0/1/2. The respective proportions of patients with vIGA-AD® ≥ 3 were 39%, 49% and 56% in the 4-mg cohort and 41%, 41% and 64% in the 2-mg cohort. Of those who were readministered the original baricitinib dose, the proportions of patients who recaptured vIGA-AD® 0/1/2 among the continuous dosing, downtitration, and treatment withdrawal groups were 80%, 85% and 88% in the 4-mg cohort and 90%, 56% and 86% in the 2-mg cohort, respectively.

Conclusions

Baricitinib allows flexibility for patients to downtitrate or stop treatment. For patients who downtitrated treatment, the majority maintained efficacy through 16 weeks. Most patients who lost efficacy with downtitration or treatment withdrawal achieved clinically relevant efficacy upon readministration of their original dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsHumansDouble-Blind MethodSeverity of Illness IndexSulfonamidesTreatment OutcomeAzetidinesPurinesPyrazoles

Substanzen

Janus Kinase InhibitorsSulfonamidesbaricitinibAzetidinesPurinesPyrazoles

Autor:innen und Institutionen

  • University Medical Center-Hamburg-Eppendorf, Hamburg, Germany.
  • Oregon Health & Science University, Portland, OR, USA.
  • Ludwig Maximillian University, Munich, Germany.
  • Department of Dermatology, Vrije Universiteit Brussel, Brussels, Belgium.
  • Innovaderm Research, Montreal, QC, Canada.
  • Sapporo Skin Clinic, Sapporo, Japan.

ORCID-Profile: Kristian Reich, Andreas Wollenberg, Jonathan I Silverberg

Förderung

  • Eli Lilly and Company

Zitieren

APA

Reich, K., Simpson, E., Wollenberg, A., Bissonnette, R., Abe, M., Cardillo, T., Janes, J., Sun, L., Chen, S., & Silverberg, J. I. (2023). Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. British Journal of Dermatology, 188(2), 208-217. https://doi.org/10.1093/bjd/ljac057

Vancouver

Reich K, Simpson E, Wollenberg A, Bissonnette R, Abe M, Cardillo T, et al. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. British Journal of Dermatology. 2023;188(2):208-217. doi:10.1093/bjd/ljac057

BibTeX
@article{Reich2023,
  author = {Reich, Kristian and Simpson, Eric and Wollenberg, Andreas and Bissonnette, Robert and Abe, Masatoshi and Cardillo, Tracy and Janes, Jonathan and Sun, Luna and Chen, Sherry and Silverberg, Jonathan I},
  title = {Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3},
  journal = {British Journal of Dermatology},
  year = {2023},
  volume = {188},
  number = {2},
  pages = {208--217},
  doi = {10.1093/bjd/ljac057}
}
Kostenlos starten →